Dan Ahrens discusses the monumental, albeit volatile, shift in U.S. cannabis regulations, specifically the reclassification of cannabis from Schedule 1 to Schedule 3. He emphasizes the potential for significant upside for U.S. cannabis stocks, including AdvisorShares Pure US Cannabis ETF (MSOS). Dan highlights key holdings like Curaleaf Holdings (CURA) and Trulieve Cannabis (TRUL), while also touching on the broader implications for banking and major exchange listings for these companies.